MilliporeSigma, Merck KGaA’s U.S. and Canada Life Science business, announced a $76 million expansion of its ADC manufacturing capabilities and capacity. The company is expanding the capacity at its Bioconjugation Center of Excellence facility in St. Louis. This investment triples existing capacity and enhances the company’s contract development and manufacturing organization (CDMO) offering. MilliporeSigma said…
MilliporeSigma opens $317M biosafety plant in Maryland
MilliporeSigma, the U.S. and Canadian Life Science unit of Merck KGaA (Darmstadt, Germany) announced today that it opened a new $317 million (€290) biosafety testing facility in Rockville, Maryland. The 23,000-square-meter facility houses biosafety testing, analytical development and cell banking manufacturing services. It consolidates labs currently spread across four buildings into one single facility. MilliporeSigma…
MilliporeSigma to invest €300M in new bioprocessing plant in South Korea
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA (Darmstadt, Germany), announced a €300 million in South Korea. The investment goes toward a new bioprocessing production center in Daejon, South Korea. It marks the largest investment by the company’s life science business sector in Asia-Pacific to date. The company expects the investment to…
MilliporeSigma introduces excipient with sugar-like flavor
The Neotame Emprove Essential NF excipient from MilliporeSigma (Burlington, Massachusetts) is a high-intensity sweetener that can be used to mask the bitter flavor of active pharmaceutical ingredients. Neotame Emprove Essential NF is a N-[N-(3,3-dimethylbutyl)-L-alpha-aspartyl]-L-phenylalanine-1-methyl ester. MilliporeSigma notes that the product is a potent, synthetic sweetener with a sugar-like flavor but is between 8,000 and 13,000…